Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation, France, December 2021 - February 2022

PROVIDER: PRJNA817806 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18425500_1.fastq.gz	Fastqsanger.gz
	SRR18425500_2.fastq.gz	Fastqsanger.gz
	SRR18425501_1.fastq.gz	Fastqsanger.gz
	SRR18425501_2.fastq.gz	Fastqsanger.gz
	SRR18425502_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 212

Similar Datasets

Project description:Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation, France, December 2021 - February 2022

| PRJNA853723 | ENA

Project description:Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation, France, December 2021 - February 2022

| PRJNA817870 | ENA

Post-December 2022 SARS-CoV-2 Systematic Variant Calling (COVID-19 Taskforce VEO)

Project description:Unfiltered Variant Calls December 2022 to February 2023 (VEO COVID-19 Taskforce)

| PRJEB57995 | ENA

Project description:VEO COVID-19 Taskforce Analysis December 2022 to February 2023

| PRJEB57999 | ENA

Post-August 2022 SARS-CoV-2 Systematic Variant Calling (COVID-19 Taskforce VEO)

Project description:Unfiltered Variant Calls From August 2022 to December 2022 (VEO COVID-19 Taskforce)

| PRJEB55349 | ENA

Immunological and Metabolic Characteristics of the Omicron Variants Infection

Project description:The Omicron variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in November 2021 in South Africa, has initiated the 5th wave of global pandemics. Here, we systemically examined immunological and metabolic characteristics of Omicron variants infection. We found Omicron resisted to neutralizing antibody targeting receptor binding domain (RBD) of wild-type SARS-CoV-2. Omicron could not be neutralized by sera of Corona Virus Disease 2019 (COVID-19) convalescent individuals who were infected with the Delta variant. Through mass spectrometry on MHC-bound peptidomes, we found that the spike protein of the Omicron variants could generate additional CD8+ T cell epitopes, compared with Delta. These epitopes could induce robust CD8+ T cell responses. Moreover, we found booster vaccination increased the cross-memory CD8+ T cell responses against Omicron. Metabolic regulome analysis of Omicron-specific T cell showed a metabolic profile that promoted memory T cell responses. Consistently, a higher fraction of memory CD8+ T cells were found in Omicron stimulated peripheral blood mononuclear cells (PBMCs). In addition, CD147 was also a receptor for the Omicron variants, and CD147 antibody inhibited infection of Omicron. CD147-mediated Omicron infection in a human CD147 transgenic mouse model induced exudative alveolar pneumonia. Taken together, our data suggested that vaccination booster and receptor blocking antibody are two effective strategies against Omicron.

2023-03-11 | PXD037955 | Pride

Project description:Filtered Variant Calls From August 2022 to December 2022 (VEO SARS-CoV-2 Taskforce)

| PRJEB55355 | ENA

undefined

Project description:Filtered Variant Calls After December 2022 (VEO SARS-CoV-2 Taskforce)

| PRJEB57993 | ENA

Proteome of cerebral thrombi retrieved in acute phase of stroke (Retro-MATISSE I)

Project description:The proteome of cerebral thrombi from patients recanalized by mechanical thrombectomy in an acute phase of stroke was carried out to determine biomarkers of stroke radio-clinical outcomes for stroke physicians (clinical outcome and mortality at 3 months, intracranial hemorrhagic transformation, etc.). Proteome of cerebral thrombi was also used to elucidate stroke physiopathology (paradoxical effect of glucose in acute phase of stroke) and evaluate recanalization treatments (intravenous thrombolysis by rt-PA and/or thrombectomy efficiency). Retro-MATISSE (Molecular Analysis of Thrombus in Ischemic Stroke prognosiS and Etiology) database was incremented by proteomic analyses of cerebral thrombi successfully retrieved from all consecutive stroke patients (n=47) with large vessel occlusion treated by mechanical thrombectomy in acute phase between December 2020 and May 2021 in the intensive care stroke unit of the University Hospital of Marseille (France).

2024-01-28 | PXD048933 | Pride

Determinants of de novo B cell responses to drifted epitopes in post-vaccination SARS-CoV-2 infections data

Project description:Vaccine-induced immunity may impact subsequent de novo responses to drifted epitopes in SARS-CoV-2 variants, but this has been difficult to quantify due to the challenges in recruiting unvaccinated control groups whose first exposure to SARS-CoV-2 is a primary infection . Through local, statewide, and national SARS-CoV-2 testing programs, we were able to recruit cohorts of individuals who had recovered from either primary or post-vaccination infections by either the Delta or Omicron BA.1 variants. Regardless of variant, we observed greater Spike-specific and neutralizing antibody responses in post-vaccination infections than in those who were infected without prior vaccination. Through analysis of variant-specific memory B cells as markers of de novo responses, we observed that Delta and Omicron BA.1 infections led to a marked shift in immunodominance in which some drifted epitopes elicited minimal responses, even in primary infections. Prior immunity through vaccination had a small negative impact on these de novo responses, but this did not correlate with cross-reactive memory B cells, arguing against competitive inhibition of naïve B cells. We conclude that dampened de novo B cell responses against drifted epitopes are mostly a function of altered immunodominance hierarchies that are apparent even in primary infections, with a more modest contribution from pre-existing immunity, perhaps due to accelerated antigen clearance.

2023-09-12 | GSE242775 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data